Neurostimulation Based On Glycemic Condition

• US 20100057158A1
• Filed: 08/26/2008
• Published: 03/04/2010
• Est. Priority Date: 08/26/2008
• Status: Abandoned Application

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Rodriguez, Rodolfo, Qu, Fujian, Bharmi, Rupinder, Wenzel, Brian Jeffrey, Farazi, Taraneh Ghaffari, Jarverud, Karin
• Application Number:
  US12/198,791
• Publication Number:
  US 20100057158A1
• Time in Patent Office: Days
• US Class Current: 607/22
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/365 controlled by a physiological parameter, e.g. heart potential evoked response A61N1/371

Abstract

A glycemic condition is indicated based on variance of a feature derived from cardiac electrogram data. Neurostimulation is then used to counteract a cardiac-related autonomic response to the glycemic condition. For example, stimulation of parasympathetic innervation may be used to counteract an autonomic sympathetic response that is associated with hypoglycemia or hyperglycemia. In addition, stimulation of sympathetic innervation may be used to counteract an autonomic parasympathetic response that is associated with hypoglycemia or hyperglycemia.

Claims

1. A method of neurostimulation, comprising:

sensing cardiac activity;

generating intracardiac electrogram data based on the sensed cardiac activity;

identifying a glycemic condition based on the intracardiac electrogram data; and

stimulating at least one nerve based on the identified glycemic condition.

2. The method of claim 1, wherein the glycemic condition comprises hypoglycemia or hyperglycemia.

3. The method of claim 1, further comprising:

characterizing the glycemic condition; and

determining whether to employ parasympathetic innervation or sympathetic innervation for the stimulation based on the characterization of the glycemic condition.

4. The method of claim 1, wherein the stimulation comprises providing parasympathetic innervation to counteract an autonomic sympathetic response associated with the glycemic condition.

5. The method of claim 1, wherein the stimulation comprises providing sympathetic innervation to counteract an autonomic parasympathetic response associated with the glycemic condition.

6. The method of claim 1, wherein the stimulation comprises enhancing or inhibiting an autonomic nervous system response.

7. The method of claim 1, wherein:

the glycemic condition comprises hypoglycemia; and

the stimulation comprises activating a parasympathetic response and/or deactivating a sympathetic response.

8. The method of claim 1, wherein:

the glycemic condition comprises hyperglycemia; and

the stimulation comprises activating a sympathetic response and/or deactivating a parasympathetic response.

9. The method of claim 1, wherein the stimulation causes a change in heart rate.

10. The method of claim 1, further comprising:

determining a severity of the glycemic condition; and

specifying at least one signal parameter for the stimulation based on the severity of the glycemic condition.

11. The method of claim 10, wherein the at least one signal parameter comprises frequency and/or amplitude.

12. The method of claim 1, further comprising:

determining whether the stimulation has mitigated the glycemic condition; and

adapting the stimulation based on the determination.

13. The method of claim 1, wherein the identification of a glycemic condition comprises detecting a variance in at least one of the group consisting of:

cardiac event duration, cardiac event amplitude, and cardiac event dispersion.

14. The method of claim 1, wherein the identification of a glycemic condition comprises generating an indication relating to variance of a cardiac feature represented by the intracardiac electrogram data.

15. The method of claim 14, wherein the cardiac feature relates to at least one of the group consisting of:

QT interval time period, T-wave timing, R-wave amplitude, R-wave area, and T-wave area.

16. The method of claim 14, further comprising:

determining whether the cardiac feature is associated with an intrinsic cardiac event or a paced cardiac event; and

normalizing the variance indication based on the determination.

17. The method of claim 1, wherein the at least one nerve carries neurotransmitters associated with at least one cardiac autonomic response.

18. The method of claim 1, wherein the stimulation of the at least one nerve comprises applying a stimulation signal to a lead implanted adjacent to at least one or the group consisting of:

a vagus nerve, an epicardial fat pad, a cardiac nerve, and a spinal cord vertebra.

19. A stimulation apparatus, comprising:

a cardiac sensing circuit that senses cardiac signals;

an electrogram processor that generates intracardiac electrogram data based on the sensed cardiac signals;

a glycemia monitor that identifies a glycemic condition based on the intracardiac electrogram data; and

a neurostimulation signal generator that generates at least one signal for stimulating at least one nerve based on the identified glycemic condition.

20. The apparatus of claim 19, wherein the glycemia monitor is further configured to:

determine a severity of the glycemic condition; and

specify frequency and/or amplitude for the at least one signal based on the severity of the glycemic condition.